(NewsDirect)
Tiziana Life Sciences Ltd (NASDAQ:TLSA)chief medical officer and chief operating officer Matthew Davis speaksto Thomas Warner from Proactive after the clinical-stagebiopharmaceutical company announced an update on the company'sprogress in treating non-active secondary progressive multiplesclerosis (MS).
The latest six-monthPET scan data reveals improvements in five out of six patients,echoing the positive results from the three-month scans. Thisbreakthrough aligns with the drug's hypothesis, as published inthe Proceedings of the National Academy of Science, which suggests thedrug works by stabilising the brain's innate immunity. From abusiness perspective, Davis suggests the findings aresignificant.
In the US, there's no FDA-approved treatmentfor this specific MS type, affecting approximately 200,000 patients.Tiziana Life Sciences is gearing up for its phase 2a programme,focusing on PET change as a primary endpoint. Davis also highlightsthat he addressed the importance of targeting neuroinflammation in MSand Alzheimer's during a keynote speech in Milan thisweek.
Contact Details
Proactive UK Ltd
+4420 7989 0813
Copyright (c) 2023 TheNewswire - All rights reserved.